Behind the Paper

LWMH Vs Apixban after LSG for chemoprophylaxis

Published in Surgery

Go to the profile of Ahmed Abdelsalam
Ahmed Abdelsalam
LWMH Vs Apixban after LSG for chemoprophylaxis
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

Share with...

...or copy the link

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Explore the Research

SpringerLink
SpringerLink SpringerLink

Comparison between low molecular weight heparin and apixaban (direct oral anticoagulant) in the prophylaxis against venous thromboembolism after laparoscopic sleeve gastrectomy - Obesity Surgery

Background Like any major operation, sleeve gastrectomy (SG) has its reported postoperative complications. Among them are venous thromboembolic complications (VTE) that may predispose to mortality. Despite the proven efficacy of the traditional anticoagulants, such as low molecular weight heparins (LMWHs) for VTE management, they have their limitations. Direct oral anticoagulants (DOACs) have been currently adopted for the management of VTE. We conducted this study to evaluate the efficacy and safety of apixaban against VTE after laparoscopic sleeve gastrectomy in comparison with LMWH. Methods This was a randomized controlled trial that included 100 adult patients who underwent SG and received LMWH (Group A) or apixaban (Group B) for VTE prophylaxis. We recorded and analyzed the postoperative events up to the 30th day after surgery. Results This study included Group A (n = 50) and Group B (n = 50). No VTE occurred in either group (0%). Postoperative bleeding was encountered in one patient of each group (2%). The follow-up venous Doppler study was unremarkable in the two groups. Conclusion Apixaban was shown to be comparable to LMWH for the prevention of VTE after LSG with similar efficacy and safety making it a promising alternative to LMWH in patients undergoing bariatric surgery.

We are excited to share our latest research:
"Comparison Between Low Molecular Weight Heparin and Apixaban in the Prophylaxis Against Venous Thromboembolism After Laparoscopic Sleeve Gastrectomy"

🔍 Key Findings:
✔️ No venous thromboembolism (VTE) events occurred in either group.
✔️ Apixaban was found to be as effective and safe as low molecular weight heparin (LMWH) for post-bariatric surgery VTE prophylaxis.
✔️ Similar rates of postoperative bleeding (2%) in both groups.
✔️ The study highlights the potential advantages of DOACs in bariatric surgery, including ease of administration and non-requirement for monitoring.

💡 Why This Matters:
Venous thromboembolism is a serious postoperative risk in bariatric surgery, and anticoagulation strategies remain a critical area of research. Our randomized controlled trial (RCT) suggests that apixaban could be a viable alternative to LMWH, offering a simpler and potentially more patient-friendly approach to VTE prophylaxis.

📖 Read the full article here: DOI: 10.1007/s11695-025-07721-y

🔬 We welcome discussions, insights, and collaborations on the use of DOACs in bariatric surgery! Have you encountered similar findings in your practice? Let’s talk!

#BariatricSurgery #VTE #Anticoagulation #Apixaban #LMWH #ObesitySurgery #DOACs #PatientSafety #SurgicalResearch

Go to the profile of Ahmed Abdelsalam
Ahmed Abdelsalam (He/Him)

I am an Associate Professor of Surgery at Cairo University’s Kasr Al-Ainy Faculty of Medicine and a consultant bariatric and minimally invasive surgeon. My clinical work focuses on advanced laparoscopic and revisional bariatric procedures, managing a high-volume obesity surgery center. I am deeply involved in research, with multiple publications in leading journals such as Obesity Surgery, Surgical Endoscopy, and BMC Surgery, covering topics from revisional techniques to postoperative outcomes and innovation in metabolic surgery. I also serve as a reviewer for several international journals, contributing to maintaining scientific rigor and advancing surgical knowledge. Through both my clinical practice and academic work, I strive to improve patient outcomes and strengthen evidence-based bariatric care globally.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Sign In Register

Follow the Topic

Surgery
Life Sciences > Health Sciences > Surgery

Related Collections

With Collections, you can get published faster and increase your visibility.

The IFSO Collection

A collection of publications by members of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and the American Society for Metabolic and Bariatric Surgery (ASMBS). **If you or one of your co-authors are members of IFSO or ASMBS, please submit your research to this topical collection for consideration in OBSU.**

Publishing Model: Hybrid

Deadline: Ongoing

Explore this Collection

Cardiometabolic Surgery

We are pleased to announce a special edition of Obesity Surgery entitled 'Cardiometabolic Surgery.' This edition is dedicated to exploring recent advancements in the understanding, diagnosis, and management of metabolic and bariatric surgery within the framework of cardiovascular diseases and cardio-renal metabolic syndrome. Furthermore, it will examine the integration of medical and endoscopic therapies within this clinical context

This special issue will also focus on advancements in both medical and surgical therapies. Topics of interest include:

  • Impact of Obesity in the cardiovascular system.
  • Reduction of CV risk.
  • Cardiometabolic surgery and Diabetes and MASH/MASLD.
  • Cardiometabolic surgery and Hypertension.
  • Cardiometabolic surgery and MI.
  • Cardiometabolic surgery and CKD.
  • Medical therapies (combined therapies).
  • Endoscopic therapies

Furthermore, we encourage contributions discussing the latest techniques in surgical intervention, such as RYGB, SG, SADI, OAGB (eventually BPT) and, endoscopic gastroplasty.

We hope to provide a comprehensive overview that will serve as a valuable resource for clinicians and researchers dedicated to improving outcomes in patients with CV diseases and Cardio-renal Metabolic Syndrome.

Publishing Model: Hybrid

Deadline: Aug 17, 2026

Explore this Collection

Recommended Content

Cookies

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.

Further information can be found in our privacy policy.

Cookie Control

Customise your preferences for any tracking technology

The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.

See the full cookie policy See the full privacy policy
More information

These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.

More information

These trackers help us to deliver personalized marketing content and to operate, serve and track ads.

More information

These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.

More information

These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.

More information

These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.